Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is China Medical System Holdings EV-to-EBITDA?
China Medical System HoldingsSTU:2M7C +3.17%78 EV-to-EBITDA is 9.11 as of Aug. 23, 2026, which is 14% above its 10-year median of 7.96. GuruFocus rates STU:2M7C with a GF Score™ of 78/100 and a GF Value™ of €1.41 (Fairly Valued). The stock has 3 warning signs investors should review. Among 739 Drug Manufacturers companies, China Medical System Holdings ranks better than 64.55% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, China Medical System Holdings's enterprise value is €2,468 Mil.
China Medical System Holdings's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €271 Mil. Therefore, China Medical System Holdings's EV-to-EBITDA for today is 9.11.
The historical rank and industry rank for China Medical System Holdings's EV-to-EBITDA or its related term are showing as below:
STU:2M7C'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 3.04 Med: 7.96 Max: 24.3
Current: 9.21
During the past 13 years, the highest EV-to-EBITDA of China Medical System Holdings was 24.30. The lowest was 3.04. And the median was 7.96.
STU:2M7C's EV-to-EBITDA is ranked better than 64.55% of 739
companies
in the Drug Manufacturers industry
Industry Median: 13.21
vs STU:2M7C: 9.21
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
China Medical System Holdings (STU:2M7C) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
China Medical System Holdings's PE Ratio (TTM) for today is calculated as:
China Medical System Holdings's share price for today is €1.30.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. China Medical System Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was €0.079.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, China Medical System Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Medical System Holdings EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, China Medical System Holdings's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where China Medical System Holdings's EV-to-EBITDA falls into.
China Medical System Holdings's current Enterprise Value is €2,468 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. China Medical System Holdings's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €271 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Medical System Holdings (STU:2M7C) has a EV-to-EBITDA of 9.11 as of Aug. 23, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on China Medical System Holdings. This is 14% above median its historical median of 7.96. Over the past decade, China Medical System Holdings' EV-to-EBITDA has ranged from 3.04 to 24.30. According to the industry distribution chart, China Medical System Holdings ranks #262 out of 739 companies in the Drug Manufacturers industry, placing it in the top 35.5%.
Is China Medical System Holdings' EV-to-EBITDA too high?
China Medical System Holdings' current EV-to-EBITDA of 9.11 is 14% above median its 10-year median of 7.96. Over the past 10 years, this metric has ranged from a low of 3.04 to a high of 24.30. The Drug Manufacturers industry median EV-to-EBITDA is 13.21. China Medical System Holdings' value of 9.11 is 31% below this industry median. Based on the distribution chart, China Medical System Holdings ranks #262 out of 739 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, China Medical System Holdings has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does China Medical System Holdings' EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, China Medical System Holdings ranks #262 out of 739 companies for EV-to-EBITDA. This puts China Medical System Holdings in the upper half of its industry. The industry median EV-to-EBITDA is 13.21. China Medical System Holdings' value of 9.11 is 31% below this benchmark. Historically, China Medical System Holdings' own EV-to-EBITDA has ranged from 3.04 to 24.30 over the past decade. While the company's 10-year median is 7.96 vs. the industry median of 13.21, China Medical System Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.21, based on 739 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Medical System Holdings's current EV-to-EBITDA of 9.11 is 31% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on China Medical System Holdings. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Medical System Holdings's current EV-to-EBITDA is 9.11, which is 14% above median its own 10-year median of 7.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Medical System Holdings stock overvalued right now?
Based on GuruFocus' analysis, China Medical System Holdings (STU:2M7C) is currently considered Fairly Valued. The stock's GF Value™ is €1.41, compared to a current price of €1.30 — trading 7.8% below its estimated fair value. The current EV-to-EBITDA is 9.11, which is 14% above median its 10-year median of 7.96 and 31% below the Drug Manufacturers industry median of 13.21. China Medical System Holdings' overall GF Score™ is 78/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For China Medical System Holdings (STU:2M7C), the current EV-to-EBITDA is 9.11 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Medical System Holdings (STU:2M7C) Overvalued in 2026?
Based on GuruFocus' analysis, China Medical System Holdings stock appears to be undervalued.
The current stock price of €1.30 is trading 7.8% below its estimated GF Value™ of €1.41.
GuruFocus considers China Medical System Holdings to be Fairly Valued.
Key valuation signals for STU:2M7C:
EV-to-EBITDA: 9.11 (14% above median its 10-year median of 7.96)
GF Value™: €1.41 vs. price of €1.30 (7.8% below fair value)
Industry Position: 31% below the Drug Manufacturers median (#262 of 739)
No single metric tells the full story. See the STU:2M7C stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Medical System Holdings Ltd is a holding company. Along with its subsidiaries, it is engaged in the research and development, production, promotion and sale of medicines. The company's reportable segments are: (i) Integrated pharmaceuticals portfolio and (ii) Skin diseases related business. The majority of the company's revenue, which consists of pharmaceutical products sales, is derived from the integrated pharmaceuticals portfolio segment.
78GF Score
Get the complete analysis for STU:2M7C
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2M7C has been successfully added to your 
